贝伐-话题@MedSci

#贝伐#

228篇内容 | 1572人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477132, encodeId=4bf214e7132f2, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤, objectType=article, longId=737805, objectId=47e8e378058e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e8e378058e, replyNumber=0, likeNumber=39, createdTime=2022-09-06, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e8e378058e, moduleTitle=Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47e8e378058e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477131, encodeId=d32f14e7131b4, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？, objectType=article, longId=732446, objectId=6cfee32446f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cfee32446f8, replyNumber=0, likeNumber=48, createdTime=2022-07-16, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cfee32446f8, moduleTitle=建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cfee32446f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477130, encodeId=49f414e713039, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题, objectType=article, longId=730174, objectId=a09fe3017471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a09fe3017471, replyNumber=0, likeNumber=54, createdTime=2022-06-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a09fe3017471, moduleTitle=肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a09fe3017471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477129, encodeId=cd8214e7129d6, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？, objectType=article, longId=729270, objectId=e19ae2927019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e19ae2927019, replyNumber=0, likeNumber=55, createdTime=2022-06-15, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e19ae2927019, moduleTitle=贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e19ae2927019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477128, encodeId=699514e71280a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=39, createdTime=2022-06-09, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477127, encodeId=318e14e7127d0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, objectType=article, longId=728685, objectId=6d07e286855f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d07e286855f, replyNumber=0, likeNumber=43, createdTime=2022-06-07, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d07e286855f, moduleTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d07e286855f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477126, encodeId=2f8714e7126b1, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, objectType=article, longId=728247, objectId=5740e2824790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5740e2824790, replyNumber=0, likeNumber=40, createdTime=2022-06-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5740e2824790, moduleTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5740e2824790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477125, encodeId=e5e714e71258d, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=35, createdTime=2022-05-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477124, encodeId=42bc14e7124cb, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？, objectType=article, longId=727345, objectId=af29e27345ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af29e27345ba, replyNumber=0, likeNumber=19, createdTime=2022-05-21, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af29e27345ba, moduleTitle=肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af29e27345ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477123, encodeId=e48f14e7123ef, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗和安罗替尼在使用时如何选择？, objectType=article, longId=727344, objectId=2fede273441e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fede273441e, replyNumber=0, likeNumber=41, createdTime=2022-05-21, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fede273441e, moduleTitle=贝伐珠单抗和安罗替尼在使用时如何选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fede273441e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477122, encodeId=81f314e7122e9, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=关于贝伐珠单抗，你想知道的全在这里, objectType=article, longId=726226, objectId=ce72e262261f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce72e262261f, replyNumber=0, likeNumber=51, createdTime=2022-05-07, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce72e262261f, moduleTitle=关于贝伐珠单抗，你想知道的全在这里, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce72e262261f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477121, encodeId=1ebe14e71210c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Clin Cancer Res：甲胎蛋白可作为肝细胞癌采用Atezolizuma+贝伐单抗治疗的预后生物标志物, objectType=article, longId=726091, objectId=2391e260910b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2391e260910b, replyNumber=0, likeNumber=40, createdTime=2022-05-05, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2391e260910b, moduleTitle=Clin Cancer Res：甲胎蛋白可作为肝细胞癌采用Atezolizuma+贝伐单抗治疗的预后生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2391e260910b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477120, encodeId=34b814e7120b6, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, objectType=article, longId=301244, objectId=cf6f3012449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6f3012449f, replyNumber=0, likeNumber=44, createdTime=2022-03-22, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6f3012449f, moduleTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf6f3012449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477119, encodeId=cdca14e7119b3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=23, createdTime=2022-03-18, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477118, encodeId=7d3314e7118d0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=33, createdTime=2022-03-15, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477117, encodeId=bbb714e711714, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=299336, objectId=5af529933624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af529933624, replyNumber=0, likeNumber=17, createdTime=2022-02-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af529933624, moduleTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af529933624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477116, encodeId=f98d14e711678, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, objectType=article, longId=299129, objectId=bdd0299129f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd0299129f0, replyNumber=0, likeNumber=34, createdTime=2022-02-20, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd0299129f0, moduleTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd0299129f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477114, encodeId=13e914e711416, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=36, createdTime=2022-02-11, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477115, encodeId=4dd814e7115ff, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, objectType=article, longId=295291, objectId=de9929529101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de9929529101, replyNumber=0, likeNumber=39, createdTime=2022-02-10, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de9929529101, moduleTitle=Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de9929529101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477113, encodeId=241c14e711396, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=34, createdTime=2022-02-07, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤

2022-09-06

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

建议收藏！贝伐珠单抗的4大常见不良反应，如何处理？

2022-07-16

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

肿瘤笔记：一文掌握关于贝伐珠单抗临床相关的70个细节问题

2022-06-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗的中国人群标准剂量是多少？你真的知道吗？

2022-06-15

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-06-09

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌

2022-06-07

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌

2022-06-01

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2022-05-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？

2022-05-21

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗和安罗替尼在使用时如何选择？

2022-05-21

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

关于贝伐珠单抗，你想知道的全在这里

2022-05-07

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Clin Cancer Res：甲胎蛋白可作为肝细胞癌采用Atezolizuma+贝伐单抗治疗的预后生物标志物

2022-05-05

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效

2022-03-22

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-03-18

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-03-15

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效

2022-02-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效

2022-02-20

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-02-11

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Transl Lung Cancer Res: 随机II期研究比较贝伐珠单抗联合不同铂类化疗方案治疗晚期非鳞状非小细胞肺癌(nsNSCLC)的疗效

2022-02-10

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-02-07

科室
- - 订阅+
  - 更多科室
工具
服务